{"gene":"RPL19","run_date":"2026-06-10T07:46:26","timeline":{"discoveries":[{"year":2016,"finding":"The eukaryote-specific intersubunit bridge eB12 is formed by contacts between the C-terminal α-helix of eL19 (RPL19) and 18S rRNA, with additional stabilizing interactions involving eS7 or uS17. The globular domain and middle region of eL19 are essential for cell viability, likely functioning in ribosome assembly. The eB12 bridge contributes to stability of ribosome subunit interactions in vitro; 60S subunits with eL19 variants defective in eB12 bridge formation failed to form 80S ribosomes regardless of Mg2+ concentration, and reassociation was improved by deacetylated tRNA.","method":"Deletion mutagenesis of eL19 in yeast, biochemical ribosome subunit reassociation assays in vitro, growth phenotype analysis, translational inhibitor sensitivity assays","journal":"Journal of molecular biology","confidence":"High","confidence_rationale":"Tier 1 / Moderate — in vitro reconstitution of subunit joining with defined mutants plus mutagenesis and multiple orthogonal phenotypic readouts in a single study","pmids":["27038511"],"is_preprint":false},{"year":2016,"finding":"RPL19 (Drosophila) physically interacts with ERH (enhancer of rudimentary homolog) as identified by yeast two-hybrid screening. The ERH sequences required for the RPL19 interaction map to the same N-terminal 24-amino-acid region necessary for nuclear localization of ERH, suggesting RPL19 may contribute to ERH nuclear targeting.","method":"Yeast two-hybrid screen; domain mapping by deletion analysis","journal":"Molecular biology international","confidence":"Low","confidence_rationale":"Tier 3 / Weak — single yeast two-hybrid assay, no reciprocal co-IP or in vivo validation of nuclear localization mechanism","pmids":["27830090"],"is_preprint":false},{"year":2011,"finding":"siRNA knockdown of RPL19 in PC-3M prostate cancer cells abrogates the malignant phenotype in vivo (xenograft growth significantly reduced) without compromising cell proliferation or apoptosis in vitro, and selectively modulates a subset of transcription factor and cellular adhesion gene networks, indicating extra-ribosomal regulatory functions of RPL19 beyond protein synthesis.","method":"siRNA knockdown, gene expression array, Western blotting, xenograft tumor growth assay","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — clean KD with defined cellular/in vivo phenotype plus transcriptomic characterization, single lab, multiple orthogonal methods","pmids":["21799931"],"is_preprint":false},{"year":1995,"finding":"The human RPL19 gene maps by FISH to chromosomal position 17q11. Promoter deletion analysis of the rat RPL19 gene revealed that far upstream sequences are required for efficient gene expression, distinguishing it from previously characterized ribosomal protein gene promoters. Both rat and human RPL19 genes have transcriptional start sites associated with CpG islands.","method":"Fluorescence in situ hybridization (FISH), promoter deletion analysis, transcriptional start site determination","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct FISH mapping and functional promoter deletion assays, single lab, two orthogonal methods","pmids":["7789970"],"is_preprint":false},{"year":2025,"finding":"NVP-BEZ235 (dual PI3K/mTOR inhibitor) induces autophagy in nephroblastoma G401 cells leading to autophagic degradation of RPL19 protein, resulting in G2/M cell cycle arrest. RPL19 overexpression partially counteracted NVP-BEZ235-mediated tumor growth inhibition in vivo, indicating that suppression of RPL19 via autophagy-mediated degradation contributes to the drug's anti-tumor mechanism.","method":"CCK-8, colony formation, EdU proliferation assays; flow cytometry cell cycle analysis; Western blot for autophagy markers and RPL19; autophagic flux assay; xenograft in vivo experiment with RPL19 overexpression rescue","journal":"Frontiers in pharmacology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple orthogonal methods including in vivo rescue experiment, single lab, no independent replication","pmids":["40771929"],"is_preprint":false},{"year":2026,"finding":"RPL19 promotes tumor cell proliferation, migration, invasion, and reduces sensitivity to trastuzumab in HER2-amplified breast cancer via upregulation of IL-4 through the transcription factor JUN. RPL19-driven IL-4 activates the IL-4/p-STAT6 signaling pathway and suppresses macrophage-mediated phagocytosis of tumor cells, further promoting tumor progression.","method":"In vitro functional assays (proliferation, migration, invasion); in vivo tumor models; mechanistic studies using transcription factor JUN regulation of IL-4; STAT6 phosphorylation analysis; macrophage phagocytosis assay","journal":"Breast cancer research : BCR","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vitro and in vivo functional assays with defined pathway (JUN→IL-4→p-STAT6), single lab, multiple orthogonal methods","pmids":["41723529"],"is_preprint":false},{"year":2025,"finding":"RPL19 was selected among large ribosomal subunit surface proteins as the optimal TRAP (translating ribosome affinity purification) tag due to its high enrichment efficiency; a stable cell line expressing EGFP-RPL19 via CRISPR knock-in specifically enriches ribosomes and translating mRNA, enabling RPL19-TRAPKI-seq to accurately detect translating mRNA profiles.","method":"CRISPR/Cas9 knock-in of EGFP-RPL19, TRAP immunoprecipitation, next-generation sequencing, rapamycin validation","journal":"Natural products and bioprospecting","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — CRISPR knock-in with validated enrichment efficiency and specificity, single lab, orthogonal sequencing validation","pmids":["40042546"],"is_preprint":false}],"current_model":"RPL19 (eL19) is a 60S large ribosomal subunit protein that forms the eukaryote-specific eB12 intersubunit bridge via its C-terminal α-helix contacting 18S rRNA and ribosomal proteins eS7/uS17, contributing to 80S ribosome assembly and subunit joining; beyond its structural/translational role, RPL19 exerts extra-ribosomal functions including regulation of gene networks governing cellular adhesion and transcription factors, promotion of tumor progression via JUN-mediated IL-4/p-STAT6 signaling, and is subject to autophagy-mediated protein degradation downstream of PI3K/mTOR inhibition."},"narrative":{"mechanistic_narrative":"RPL19 (eL19) is a structural protein of the 60S large ribosomal subunit that mediates 80S ribosome assembly and intersubunit joining [PMID:27038511]. Its C-terminal α-helix forms the eukaryote-specific eB12 intersubunit bridge through contacts with 18S rRNA and the ribosomal proteins eS7/uS17, and 60S subunits carrying eB12-defective eL19 variants fail to associate with 40S subunits regardless of Mg2+ concentration; the globular and middle domains are independently required for viability and ribosome assembly [PMID:27038511]. Its surface accessibility on the assembled ribosome makes EGFP-tagged RPL19 an efficient affinity handle for translating-ribosome purification (TRAP) [PMID:40042546]. Beyond translation, RPL19 carries out extra-ribosomal regulatory functions: its depletion selectively reshapes transcription-factor and cell-adhesion gene networks and abrogates tumor xenograft growth without altering proliferation or apoptosis in vitro [PMID:21799931], and in HER2-amplified breast cancer it drives tumor proliferation, migration, invasion, and trastuzumab resistance by upregulating IL-4 via the transcription factor JUN, activating IL-4/p-STAT6 signaling and suppressing macrophage phagocytosis of tumor cells [PMID:41723529]. RPL19 protein is degraded through autophagy downstream of PI3K/mTOR inhibition, contributing to drug-induced G2/M arrest and tumor suppression [PMID:40771929].","teleology":[{"year":1995,"claim":"Established the genomic and transcriptional identity of RPL19, showing its expression depends on regulatory architecture distinct from other ribosomal protein genes.","evidence":"FISH chromosomal mapping and promoter deletion analysis of rat and human RPL19 genes","pmids":["7789970"],"confidence":"Medium","gaps":["Did not identify the trans-acting factors binding the far-upstream sequences","No link between transcriptional regulation and protein function"]},{"year":2011,"claim":"Revealed that RPL19 has extra-ribosomal regulatory roles, since its knockdown blocked tumor growth in vivo and remodeled transcription-factor/adhesion gene networks without affecting basal proliferation or apoptosis.","evidence":"siRNA knockdown with gene expression arrays and prostate cancer xenografts","pmids":["21799931"],"confidence":"Medium","gaps":["Direct molecular targets mediating the network changes not defined","Mechanism separating extra-ribosomal from translational function unresolved"]},{"year":2016,"claim":"Defined the structural role of RPL19 in ribosome biogenesis, showing its C-terminal α-helix forms the eB12 intersubunit bridge required for 80S formation.","evidence":"Deletion mutagenesis in yeast plus in vitro subunit reassociation and phenotypic assays","pmids":["27038511"],"confidence":"High","gaps":["Based on yeast eL19; human-specific structural confirmation not shown in corpus","Functional consequence of eB12 disruption on translational fidelity not detailed"]},{"year":2016,"claim":"Identified a candidate physical partner (ERH), raising the possibility that RPL19 contributes to nuclear targeting of an interacting protein.","evidence":"Yeast two-hybrid screen and deletion domain mapping in Drosophila","pmids":["27830090"],"confidence":"Low","gaps":["Single yeast two-hybrid assay without reciprocal co-IP or in vivo validation","Proposed role in ERH nuclear localization not tested directly"]},{"year":2025,"claim":"Connected RPL19 abundance to drug response by showing it is degraded via autophagy after PI3K/mTOR inhibition, contributing to cell cycle arrest and tumor suppression.","evidence":"NVP-BEZ235 treatment of nephroblastoma cells with autophagic flux assays and in vivo RPL19 overexpression rescue","pmids":["40771929"],"confidence":"Medium","gaps":["Autophagy receptor selecting RPL19 for degradation unknown","Whether degraded pool is ribosomal or free RPL19 not distinguished"]},{"year":2025,"claim":"Exploited RPL19's exposed position on the large subunit as an optimal TRAP tag for purifying translating ribosomes and profiling translated mRNA.","evidence":"CRISPR knock-in of EGFP-RPL19, TRAP immunoprecipitation, and sequencing with rapamycin validation","pmids":["40042546"],"confidence":"Medium","gaps":["A methodological application rather than new mechanistic function","Did not address whether tagging perturbs ribosome function"]},{"year":2026,"claim":"Defined a signaling cascade for RPL19's pro-tumor activity, showing it upregulates IL-4 through JUN to activate IL-4/p-STAT6 signaling and suppress macrophage phagocytosis.","evidence":"In vitro proliferation/migration/invasion assays, in vivo tumor models, and macrophage phagocytosis assays in HER2-amplified breast cancer","pmids":["41723529"],"confidence":"Medium","gaps":["How RPL19 mechanistically controls JUN activity not resolved","Single lab without independent replication"]},{"year":null,"claim":"It remains unresolved how RPL19's structural ribosomal role mechanistically relates to its extra-ribosomal transcriptional and tumor-promoting activities.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural or biochemical link between free RPL19 and gene-network regulation","Direct molecular targets of extra-ribosomal RPL19 unidentified"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0]}],"localization":[{"term_id":"GO:0005840","term_label":"ribosome","supporting_discovery_ids":[0,6]}],"pathway":[{"term_id":"R-HSA-392499","term_label":"Metabolism of proteins","supporting_discovery_ids":[0]}],"complexes":["60S large ribosomal subunit","80S ribosome"],"partners":["ERH","ES7","US17"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"P84098","full_name":"Large ribosomal subunit protein eL19","aliases":["60S ribosomal protein L19"],"length_aa":196,"mass_kda":23.5,"function":"Component of the large ribosomal subunit (PubMed:23636399, PubMed:32669547). The ribosome is a large ribonucleoprotein complex responsible for the synthesis of proteins in the cell (PubMed:23636399, PubMed:32669547)","subcellular_location":"Cytoplasm","url":"https://www.uniprot.org/uniprotkb/P84098/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/RPL19","classification":"Common Essential","n_dependent_lines":1207,"n_total_lines":1208,"dependency_fraction":0.9991721854304636},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000108298","cell_line_id":"CID001738","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleolus_gc","grade":2}],"interactors":[{"gene":"CTCF","stoichiometry":10.0},{"gene":"EIF2S3","stoichiometry":10.0},{"gene":"EMC9","stoichiometry":10.0},{"gene":"RPL11","stoichiometry":10.0},{"gene":"SRP72","stoichiometry":10.0},{"gene":"RPL35","stoichiometry":10.0},{"gene":"RPL28","stoichiometry":10.0},{"gene":"RPL21","stoichiometry":10.0},{"gene":"RPL13A;RPL13A","stoichiometry":10.0},{"gene":"RPL34","stoichiometry":10.0}],"url":"https://opencell.sf.czbiohub.org/target/CID001738","total_profiled":1310},"omim":[{"mim_id":"602326","title":"RIBOSOMAL PROTEIN L23A; RPL23A","url":"https://www.omim.org/entry/602326"},{"mim_id":"180466","title":"RIBOSOMAL PROTEIN L19; RPL19","url":"https://www.omim.org/entry/180466"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Enhanced","locations":[{"location":"Nucleoli","reliability":"Enhanced"},{"location":"Cytosol","reliability":"Enhanced"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/RPL19"},"hgnc":{"alias_symbol":["FLJ27452","MGC71997","DKFZp779D216","L19","eL19"],"prev_symbol":[]},"alphafold":{"accession":"P84098","domains":[{"cath_id":"1.10.1650.10","chopping":"3-51","consensus_level":"high","plddt":95.4263,"start":3,"end":51},{"cath_id":"1.10.1200.240","chopping":"90-190","consensus_level":"medium","plddt":95.7657,"start":90,"end":190}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P84098","model_url":"https://alphafold.ebi.ac.uk/files/AF-P84098-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P84098-F1-predicted_aligned_error_v6.png","plddt_mean":94.75},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=RPL19","jax_strain_url":"https://www.jax.org/strain/search?query=RPL19"},"sequence":{"accession":"P84098","fasta_url":"https://rest.uniprot.org/uniprotkb/P84098.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P84098/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P84098"}},"corpus_meta":[{"pmid":"26779226","id":"PMC_26779226","title":"Plant Ribosomal Proteins, RPL12 and RPL19, Play a Role in Nonhost Disease Resistance against Bacterial Pathogens.","date":"2016","source":"Frontiers in plant science","url":"https://pubmed.ncbi.nlm.nih.gov/26779226","citation_count":67,"is_preprint":false},{"pmid":"21799931","id":"PMC_21799931","title":"siRNA knockdown of ribosomal protein gene RPL19 abrogates the aggressive phenotype of human prostate cancer.","date":"2011","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/21799931","citation_count":48,"is_preprint":false},{"pmid":"7789970","id":"PMC_7789970","title":"The L19 ribosomal protein gene (RPL19): gene organization, chromosomal mapping, and novel promoter region.","date":"1995","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/7789970","citation_count":36,"is_preprint":false},{"pmid":"27038511","id":"PMC_27038511","title":"The Functional Role of eL19 and eB12 Intersubunit Bridge in the Eukaryotic Ribosome.","date":"2016","source":"Journal of molecular biology","url":"https://pubmed.ncbi.nlm.nih.gov/27038511","citation_count":16,"is_preprint":false},{"pmid":"27830090","id":"PMC_27830090","title":"Drosophila Enhancer of Rudimentary Homolog, ERH, Is a Binding Partner of RPS3, RPL19, and DDIT4, Suggesting a Mechanism for the Nuclear Localization of ERH.","date":"2016","source":"Molecular biology international","url":"https://pubmed.ncbi.nlm.nih.gov/27830090","citation_count":8,"is_preprint":false},{"pmid":"37679739","id":"PMC_37679739","title":"Analysis of the stability of the reference genes GAPDH, SDHA and RPL-19 in sheep from a semi-arid region infected by gastrointestinal nematodes.","date":"2023","source":"BMC veterinary research","url":"https://pubmed.ncbi.nlm.nih.gov/37679739","citation_count":4,"is_preprint":false},{"pmid":"40771929","id":"PMC_40771929","title":"Dual PI3K/mTOR inhibitor NVP-BEZ235 induces cell cycle arrest via autophagy mediated protein degradation of RPL19 in nephroblastoma cell.","date":"2025","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/40771929","citation_count":0,"is_preprint":false},{"pmid":"40042546","id":"PMC_40042546","title":"Advanced RPL19-TRAPKI-seq method reveals mechanism of action of bioactive compounds.","date":"2025","source":"Natural products and bioprospecting","url":"https://pubmed.ncbi.nlm.nih.gov/40042546","citation_count":0,"is_preprint":false},{"pmid":"41723529","id":"PMC_41723529","title":"Mechanism of IL-4 mediated RPL19 promoting malignant progression in HER2 positive breast cancer.","date":"2026","source":"Breast cancer research : BCR","url":"https://pubmed.ncbi.nlm.nih.gov/41723529","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":6525,"output_tokens":1972,"usd":0.024577,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":8977,"output_tokens":2422,"usd":0.052718,"stage2_stop_reason":"end_turn"},"total_usd":0.077295,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"The eukaryote-specific intersubunit bridge eB12 is formed by contacts between the C-terminal α-helix of eL19 (RPL19) and 18S rRNA, with additional stabilizing interactions involving eS7 or uS17. The globular domain and middle region of eL19 are essential for cell viability, likely functioning in ribosome assembly. The eB12 bridge contributes to stability of ribosome subunit interactions in vitro; 60S subunits with eL19 variants defective in eB12 bridge formation failed to form 80S ribosomes regardless of Mg2+ concentration, and reassociation was improved by deacetylated tRNA.\",\n      \"method\": \"Deletion mutagenesis of eL19 in yeast, biochemical ribosome subunit reassociation assays in vitro, growth phenotype analysis, translational inhibitor sensitivity assays\",\n      \"journal\": \"Journal of molecular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — in vitro reconstitution of subunit joining with defined mutants plus mutagenesis and multiple orthogonal phenotypic readouts in a single study\",\n      \"pmids\": [\"27038511\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"RPL19 (Drosophila) physically interacts with ERH (enhancer of rudimentary homolog) as identified by yeast two-hybrid screening. The ERH sequences required for the RPL19 interaction map to the same N-terminal 24-amino-acid region necessary for nuclear localization of ERH, suggesting RPL19 may contribute to ERH nuclear targeting.\",\n      \"method\": \"Yeast two-hybrid screen; domain mapping by deletion analysis\",\n      \"journal\": \"Molecular biology international\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 / Weak — single yeast two-hybrid assay, no reciprocal co-IP or in vivo validation of nuclear localization mechanism\",\n      \"pmids\": [\"27830090\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"siRNA knockdown of RPL19 in PC-3M prostate cancer cells abrogates the malignant phenotype in vivo (xenograft growth significantly reduced) without compromising cell proliferation or apoptosis in vitro, and selectively modulates a subset of transcription factor and cellular adhesion gene networks, indicating extra-ribosomal regulatory functions of RPL19 beyond protein synthesis.\",\n      \"method\": \"siRNA knockdown, gene expression array, Western blotting, xenograft tumor growth assay\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — clean KD with defined cellular/in vivo phenotype plus transcriptomic characterization, single lab, multiple orthogonal methods\",\n      \"pmids\": [\"21799931\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"The human RPL19 gene maps by FISH to chromosomal position 17q11. Promoter deletion analysis of the rat RPL19 gene revealed that far upstream sequences are required for efficient gene expression, distinguishing it from previously characterized ribosomal protein gene promoters. Both rat and human RPL19 genes have transcriptional start sites associated with CpG islands.\",\n      \"method\": \"Fluorescence in situ hybridization (FISH), promoter deletion analysis, transcriptional start site determination\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct FISH mapping and functional promoter deletion assays, single lab, two orthogonal methods\",\n      \"pmids\": [\"7789970\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"NVP-BEZ235 (dual PI3K/mTOR inhibitor) induces autophagy in nephroblastoma G401 cells leading to autophagic degradation of RPL19 protein, resulting in G2/M cell cycle arrest. RPL19 overexpression partially counteracted NVP-BEZ235-mediated tumor growth inhibition in vivo, indicating that suppression of RPL19 via autophagy-mediated degradation contributes to the drug's anti-tumor mechanism.\",\n      \"method\": \"CCK-8, colony formation, EdU proliferation assays; flow cytometry cell cycle analysis; Western blot for autophagy markers and RPL19; autophagic flux assay; xenograft in vivo experiment with RPL19 overexpression rescue\",\n      \"journal\": \"Frontiers in pharmacology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple orthogonal methods including in vivo rescue experiment, single lab, no independent replication\",\n      \"pmids\": [\"40771929\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"RPL19 promotes tumor cell proliferation, migration, invasion, and reduces sensitivity to trastuzumab in HER2-amplified breast cancer via upregulation of IL-4 through the transcription factor JUN. RPL19-driven IL-4 activates the IL-4/p-STAT6 signaling pathway and suppresses macrophage-mediated phagocytosis of tumor cells, further promoting tumor progression.\",\n      \"method\": \"In vitro functional assays (proliferation, migration, invasion); in vivo tumor models; mechanistic studies using transcription factor JUN regulation of IL-4; STAT6 phosphorylation analysis; macrophage phagocytosis assay\",\n      \"journal\": \"Breast cancer research : BCR\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vitro and in vivo functional assays with defined pathway (JUN→IL-4→p-STAT6), single lab, multiple orthogonal methods\",\n      \"pmids\": [\"41723529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"RPL19 was selected among large ribosomal subunit surface proteins as the optimal TRAP (translating ribosome affinity purification) tag due to its high enrichment efficiency; a stable cell line expressing EGFP-RPL19 via CRISPR knock-in specifically enriches ribosomes and translating mRNA, enabling RPL19-TRAPKI-seq to accurately detect translating mRNA profiles.\",\n      \"method\": \"CRISPR/Cas9 knock-in of EGFP-RPL19, TRAP immunoprecipitation, next-generation sequencing, rapamycin validation\",\n      \"journal\": \"Natural products and bioprospecting\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — CRISPR knock-in with validated enrichment efficiency and specificity, single lab, orthogonal sequencing validation\",\n      \"pmids\": [\"40042546\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"RPL19 (eL19) is a 60S large ribosomal subunit protein that forms the eukaryote-specific eB12 intersubunit bridge via its C-terminal α-helix contacting 18S rRNA and ribosomal proteins eS7/uS17, contributing to 80S ribosome assembly and subunit joining; beyond its structural/translational role, RPL19 exerts extra-ribosomal functions including regulation of gene networks governing cellular adhesion and transcription factors, promotion of tumor progression via JUN-mediated IL-4/p-STAT6 signaling, and is subject to autophagy-mediated protein degradation downstream of PI3K/mTOR inhibition.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"RPL19 (eL19) is a structural protein of the 60S large ribosomal subunit that mediates 80S ribosome assembly and intersubunit joining [#0]. Its C-terminal α-helix forms the eukaryote-specific eB12 intersubunit bridge through contacts with 18S rRNA and the ribosomal proteins eS7/uS17, and 60S subunits carrying eB12-defective eL19 variants fail to associate with 40S subunits regardless of Mg2+ concentration; the globular and middle domains are independently required for viability and ribosome assembly [#0]. Its surface accessibility on the assembled ribosome makes EGFP-tagged RPL19 an efficient affinity handle for translating-ribosome purification (TRAP) [#6]. Beyond translation, RPL19 carries out extra-ribosomal regulatory functions: its depletion selectively reshapes transcription-factor and cell-adhesion gene networks and abrogates tumor xenograft growth without altering proliferation or apoptosis in vitro [#2], and in HER2-amplified breast cancer it drives tumor proliferation, migration, invasion, and trastuzumab resistance by upregulating IL-4 via the transcription factor JUN, activating IL-4/p-STAT6 signaling and suppressing macrophage phagocytosis of tumor cells [#5]. RPL19 protein is degraded through autophagy downstream of PI3K/mTOR inhibition, contributing to drug-induced G2/M arrest and tumor suppression [#4].\",\n  \"teleology\": [\n    {\n      \"year\": 1995,\n      \"claim\": \"Established the genomic and transcriptional identity of RPL19, showing its expression depends on regulatory architecture distinct from other ribosomal protein genes.\",\n      \"evidence\": \"FISH chromosomal mapping and promoter deletion analysis of rat and human RPL19 genes\",\n      \"pmids\": [\"7789970\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Did not identify the trans-acting factors binding the far-upstream sequences\", \"No link between transcriptional regulation and protein function\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Revealed that RPL19 has extra-ribosomal regulatory roles, since its knockdown blocked tumor growth in vivo and remodeled transcription-factor/adhesion gene networks without affecting basal proliferation or apoptosis.\",\n      \"evidence\": \"siRNA knockdown with gene expression arrays and prostate cancer xenografts\",\n      \"pmids\": [\"21799931\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct molecular targets mediating the network changes not defined\", \"Mechanism separating extra-ribosomal from translational function unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined the structural role of RPL19 in ribosome biogenesis, showing its C-terminal α-helix forms the eB12 intersubunit bridge required for 80S formation.\",\n      \"evidence\": \"Deletion mutagenesis in yeast plus in vitro subunit reassociation and phenotypic assays\",\n      \"pmids\": [\"27038511\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Based on yeast eL19; human-specific structural confirmation not shown in corpus\", \"Functional consequence of eB12 disruption on translational fidelity not detailed\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Identified a candidate physical partner (ERH), raising the possibility that RPL19 contributes to nuclear targeting of an interacting protein.\",\n      \"evidence\": \"Yeast two-hybrid screen and deletion domain mapping in Drosophila\",\n      \"pmids\": [\"27830090\"],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"Single yeast two-hybrid assay without reciprocal co-IP or in vivo validation\", \"Proposed role in ERH nuclear localization not tested directly\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Connected RPL19 abundance to drug response by showing it is degraded via autophagy after PI3K/mTOR inhibition, contributing to cell cycle arrest and tumor suppression.\",\n      \"evidence\": \"NVP-BEZ235 treatment of nephroblastoma cells with autophagic flux assays and in vivo RPL19 overexpression rescue\",\n      \"pmids\": [\"40771929\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Autophagy receptor selecting RPL19 for degradation unknown\", \"Whether degraded pool is ribosomal or free RPL19 not distinguished\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Exploited RPL19's exposed position on the large subunit as an optimal TRAP tag for purifying translating ribosomes and profiling translated mRNA.\",\n      \"evidence\": \"CRISPR knock-in of EGFP-RPL19, TRAP immunoprecipitation, and sequencing with rapamycin validation\",\n      \"pmids\": [\"40042546\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"A methodological application rather than new mechanistic function\", \"Did not address whether tagging perturbs ribosome function\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Defined a signaling cascade for RPL19's pro-tumor activity, showing it upregulates IL-4 through JUN to activate IL-4/p-STAT6 signaling and suppress macrophage phagocytosis.\",\n      \"evidence\": \"In vitro proliferation/migration/invasion assays, in vivo tumor models, and macrophage phagocytosis assays in HER2-amplified breast cancer\",\n      \"pmids\": [\"41723529\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How RPL19 mechanistically controls JUN activity not resolved\", \"Single lab without independent replication\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unresolved how RPL19's structural ribosomal role mechanistically relates to its extra-ribosomal transcriptional and tumor-promoting activities.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural or biochemical link between free RPL19 and gene-network regulation\", \"Direct molecular targets of extra-ribosomal RPL19 unidentified\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005840\", \"supporting_discovery_ids\": [0, 6]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-392499\", \"supporting_discovery_ids\": [0]}\n    ],\n    \"complexes\": [\"60S large ribosomal subunit\", \"80S ribosome\"],\n    \"partners\": [\"ERH\", \"eS7\", \"uS17\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":5,"faith_total":5,"faith_pct":100.0}}